Collaborative Practice in the Management of Patients with Gastrointestinal and Pancreatic Neuroendocrine Tumors
November 7, 2015
Learning Objectives
- Discuss how medical therapies fit within the wider range of treatment options available to patients with gastrointestinal or pancreatic neuroendocrine tumors
- Define the role of mTOR inhibitors and tyrosine kinase inhibitors in patients with recurrent disease
- Review the role of somatostatin analogs in patients with both functional and nonfunctional tumors
- Describe best practices for preventing choloecystitis and other adverse reactions associated with medical therapy for pNETs
- Recall key laboratory and imaging studies recommended for patients being trated for pNETs
United States
Jennifer Ang Chan, MD, MPH
Robin Sommers, NP
Available Credit
- 1.00 AANP
- 0.67 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC